Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Keros Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapeutics that modulate signaling pathways within the transforming growth factor‑beta (TGF‑β) superfamily. The company operates within the biopharmaceutical and life sciences industries, with a primary emphasis on developing biologic therapies for hematologic disorders and cardiopulmonary diseases with significant unmet medical need. Its core approach centers on engineered ligand trap proteins designed to selectively regulate disease‑relevant signaling.
The company’s principal revenue drivers are its clinical development programs, as it does not generate product sales and relies primarily on equity financing. Keros targets patient populations with conditions such as anemia associated with myelodysplastic syndromes and myelofibrosis, as well as pulmonary arterial hypertension. Its strategic positioning is based on proprietary protein engineering capabilities and deep specialization in TGF‑β biology. Keros was founded in 2015 and emerged from scientific research and company‑building efforts supported by venture capital, evolving into a publicly traded company following its initial public offering in 2020.
Business Operations
Keros conducts its operations as a single integrated business focused on drug discovery and clinical development. Its core business activities include preclinical research, clinical trials management, regulatory strategy, and manufacturing oversight through third‑party partners. The company’s leading product candidates include KER‑050 (cibotercept) for hematologic disorders and KER‑012 for pulmonary arterial hypertension, both of which are in clinical development stages. The company does not currently operate commercial manufacturing or sales infrastructure.
Operationally, Keros primarily conducts research and development activities in the United States, while utilizing contract research organizations and contract manufacturing organizations to support clinical trials and production. The company controls proprietary biologic assets and intellectual property related to ligand trap technology. Public disclosures indicate no material revenue‑generating subsidiaries, and information regarding major long‑term commercial partnerships or joint ventures remains limited; where referenced, details are data inconclusive based on available public sources.
Strategic Position & Investments
Keros’ strategic direction is centered on advancing its clinical pipeline through mid‑ and late‑stage trials while expanding the potential applications of its ligand trap platform. Growth initiatives focus on demonstrating clinical efficacy and safety in targeted indications and selectively broadening development into adjacent disease areas where TGF‑β signaling plays a key role. The company allocates the majority of its capital toward research and development expenditures.
Investment activity primarily consists of internal pipeline development rather than external acquisitions. Keros has historically evaluated strategic collaborations to support development or regional commercialization, but no transformative acquisitions have been confirmed in public filings. The company is positioned at the intersection of hematology and cardiopulmonary therapeutics, with emerging exposure to advanced biologics engineering rather than digital or device‑based technologies.
Geographic Footprint
Keros Therapeutics is headquartered in Lexington, Massachusetts, within the United States, and its executive leadership and research teams are primarily based there. The company’s operational footprint is concentrated in North America, reflecting its status as a development‑stage biotechnology firm.
Internationally, Keros maintains a clinical and regulatory presence through global clinical trial sites and third‑party service providers across Europe and other regions as required by study design. While it does not report dedicated international offices, its investigational programs give it indirect operational influence in multiple continents through trial enrollment and regulatory engagement.
Leadership & Governance
Keros was founded by a group of biotechnology executives and scientific leaders with expertise in immunology and protein biology, with early formation support from venture capital sponsors. The leadership team emphasizes a science‑driven culture focused on disciplined clinical execution and long‑term value creation through biologic innovation.
Key members of the leadership team, as reported in recent public filings, include:
- Jasbir S. Seehra, Ph.D. – President and Chief Executive Officer
- Laura Brege – Chief Financial Officer
- Steven Deitcher, M.D. – Chief Medical Officer
- John McGee – Chief Operating Officer
Public disclosures reflect continuity in strategic vision centered on advancing differentiated biologics; however, certain executive role timelines show minor variation across sources, and data is inconclusive based on available public sources where discrepancies exist.